Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM)

NCT01358084 is registered in ClinicalTrials.gov with AGC Biologics S.p.A. as lead sponsor.

NCT NCT01358084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01358084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM)
Lead sponsor
AGC Biologics S.p.A.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
December 5, 2018
Enrollment
137 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant pleural mesothelioma